These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 36527456

  • 1. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
    Sun Y, Yue L, Hu W.
    Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C, Li S, Huang T, Lin H, Jiang Z, He Y, Yuan J, An H.
    J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
    [Abstract] [Full Text] [Related]

  • 3. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
    Dong SQ, Singh TP, Wei X, Yao H, Wang HL.
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of Vonoprazan-based treatment of Helicobacter pylori infection: a systematic review and network meta-analysis.
    Huang S, Li B, Pang XY, Gao WW.
    BMC Infect Dis; 2024 Sep 11; 24(1):953. PubMed ID: 39261752
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
    Shinozaki S, Kobayashi Y, Osawa H, Sakamoto H, Hayashi Y, Lefor AK, Yamamoto H.
    Digestion; 2021 Sep 11; 102(3):319-325. PubMed ID: 31914442
    [Abstract] [Full Text] [Related]

  • 6. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
    Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, Nahata MC.
    Helicobacter; 2024 Sep 11; 29(3):e13094. PubMed ID: 38790090
    [Abstract] [Full Text] [Related]

  • 7. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis.
    Kanu JE, Soldera J.
    World J Gastroenterol; 2024 Mar 07; 30(9):1213-1223. PubMed ID: 38577188
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y, Shimoyama T, Mizuki I.
    Scand J Gastroenterol; 2017 Feb 07; 52(2):238-241. PubMed ID: 27806639
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
    Jung YS, Kim EH, Park CH.
    Aliment Pharmacol Ther; 2017 Jul 07; 46(2):106-114. PubMed ID: 28497487
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials.
    Zhou BG, Mei YZ, Jiang X, Zheng AJ, Ding YB.
    Saudi J Gastroenterol; 2023 Jul 07; 29(6):347-357. PubMed ID: 37602635
    [Abstract] [Full Text] [Related]

  • 15. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K.
    Digestion; 2020 Jul 07; 101(6):743-751. PubMed ID: 31434101
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
    Han S, Deng Z, Cheung K, Lyu T, Chan P, Li Y, Ni L, Luo X, Li K.
    BMC Gastroenterol; 2023 Jul 07; 23(1):231. PubMed ID: 37420205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.